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Abstract
Background: Diarrhea is a leading cause of mortality in children under 5 years along with its long-term impact on
growth and cognitive development. Despite advances in the understanding of diarrheal disorders and
management strategies, globally nearly 750,000 children die annually as a consequence of diarrhea.
Methods: We conducted a systematic review of the efficacy and effectiveness studies. We used a standardized
abstraction and grading format and performed meta-analyses for all outcomes. The estimated effect of cholera,
shigella, Enterotoxigenic Escherichia coli (ETEC) and rotavirus vaccines was determined by applying the standard
Child Health Epidemiology Reference Group (CHERG) rules.
Results: A total of 24 papers were selected and analyzed for all the four vaccines. Based on the evidence, we
propose a 74% mortality reduction in rotavirus specific mortality, 52% reduction in cholera incidence due to their
respective vaccines. We did not find sufficient evidence and a suitable outcome to project mortality reductions for
cholera, ETEC and shigella in children under 5 years.
Conclusion: Vaccines for rotavirus and cholera have the potential to reduce diarrhea morbidity and mortality
burden. But there is no substantial evidence of efficacy for ETEC and shigella vaccines, although several promising
vaccine concepts are moving from the development and testing pipeline towards efficacy and Phase 3 trials.
Introduction
Diarrhea is the leading cause of mortality in children
under 5 years along with its long-term impact on growth
and cognitive development. Despite advances in the
understanding of diarrheal disorders and management
strategies; globally 0.75 million children die annually as a
consequence of diarrhea [1]. The number of cholera
cases reported to World Health Organization (WHO)
annually has remained relatively constant since 1995,
varying from 100,000 to 300,000 cases per year [2]. An
estimated 1 million deaths (60% in children under 5) and
165 million cases of dysentery annually were estimated to
occur due to shigella [3], while more recent estimates
place the shigella disease burden at about 90 million epi-
sodes and 108,000 deaths per year [2]. Enterotoxigenic
Escherichia coli (ETEC) was thought to account for an
estimated 200 million diarrhea episodes and 380,000
deaths annually [4], while a recent estimate suggests a
lower figure of 170,000 deaths every year [2]. Rotavirus is
the most common cause of severe dehydrating diarrhea
in young children globally accounting for an estimated
527,000 (475 000-580 000) deaths each year, mostly in
children under the age of two years [2]. Collectively these
four organisms account for a great number of cases of
diarrhea across the world and vaccines targeting the
most common strains of all these pathogens are currently
being developed, improved and undergoing trials across
the globe.
Older generation injectable cholera vaccines have been
abandoned since the 1970s owing to their limited efficacy
and local side effects. Oral Cholera Vaccines (OCV) are
good candidates for the control of cholera particularly in
endemic areas. For example the inactivated or killed whole
cell plus recombinant cholera toxin B subunit vaccine
(rBS-WC) and the killed oral cholera vaccine (WC) has
shown success in trials in Mozambique [5] and Vietnam
respectively [6]. The potential for use of cholera vaccines
is immense in public health, especially due to its herd
immunity effect and recent research indicates that with
this herd protection, even moderate coverage levels of
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targeted populations with killed OCVs may result in
virtually complete control of cholera [7,8].
There are four different species and 47 antigenically
distinct serotypes of Shigella, divided on the basis of dif-
ferences in O antigen of their lipopolysaccharide which
are S. dysenteriae (13 serotypes), S. flexneri (15 sero-
types), S. boydii (18 serotypes), and S. sonnei (1 serotype).
A safe and effective shigella vaccine offers great potential
for controlling shigellosis and the potential of oral and
parenteral shigella vaccines for conferring a high degree
of serotype-specific immunity has been confirmed in
some field trials [9-11]. The presence of 15 serotypes of
S. flexneri is a barrier for vaccine development [12],
although there is evidence of serologic cross-reactivity in
humans [11] and cross-protection among S. flexneri sero-
types in animals [13], suggesting that broad S. flexneri
protection may be possible. In addition, recent pre-clini-
cal animal studies also suggests that conserved Shigella
invasion proteins may be able to induce broad protection
against both S. flexneri and S. sonnei serotypes when
given parenterally with a mucosal adjuvant [14].
Like Shigella, the incidence of ETEC infection peaks in
early life and declines thereafter, suggesting that there
may be natural immunity after repeated exposures
[15,16]. ETEC associated morbidity is extremely high in
many endemic countries with children experiencing 1-2
symptomatic episodes per child per year through the
first 2-3 years of life. The high ETEC burden has also
been associated with nutritional deficiency; both low
weight for age as well as low height for age [16,17]. An
inactivated whole cell ETEC vaccine designed to induce
immune responses against both the Heat Labile toxin
(LT)and common colonization factors protected trave-
lers against more moderate to severe diarrhea in two
trials (protective efficacy of ~70%), but did not confer
protection among young children and infants in Egypt
(protective efficacy of ~20%) [18,19].
Prevalence of rotavirus related gastro-enteritis is similar
in developed and developing countries, showing that it has
little or no association with sanitation systems, as opposed
to the former three organisms. This makes vaccination
even more important and studies have shown that vacci-
nation contributes significantly towards reduction in cases
of rotavirus related illnesses in the developed world.
Efforts to develop rotavirus vaccine began in 1980s and
were introduced in 1990s but were withdrawn after asso-
ciation with increased risk of intussusception, and this led
to the development and testing of new vaccines for poten-
tial use in a range of settings. Recent Phase III trials of the
monovalent rotavirus vaccine in Malawi and South Africa
[20] have also shown a vaccine efficacy of 77% against
severe rotavirus infection in South Africa and lower (50%)
efficacy in Malawi. A previous review of six studies [21]
based on the Lives Saved Tools (LiST) rules suggests that
these vaccines are associated with a 74% reduction in rota-
virus related diarrhea mortality but also indicated that pro-
tective efficacy may be lower in regions with high child
mortality rates and residual burdens of bacterial diarrhea .
We conducted a systematic review followed by a
meta-analysis of the published efficacy and effectiveness
trials of vaccines against cholera, ETEC, shigella and
rotavirus to provide a best possible impact of these
interventions on cause specific mortality. We reviewed
the available literature and evaluated the quality of
included studies according to the Child Health Epide-
miology Reference Group (CHERG) adaptation, Assess-
ments, Development and Education (GRADE) criteria
[22]. We performed new reviews for cholera, shigella
and ETEC vaccines, while updated the existing LiST
review on rotavirus vaccines [21].
Methods
We systematically reviewed all published literature up to
March 2012 to identify the efficacy and effectiveness stu-
dies describing the effects of vaccines related to cholera,
shigella, ETEC and rotavirus in children less than or
equal to 5 years. We specifically evaluated the evidence
for vaccine related outcomes studies using recent recom-
mendations from a GRADE working group on vaccines
[23]. Following CHERG Systematic Review Guidelines,
we searched PubMed, Cochrane Libraries, Embase and
WHO Regional Databases and additional studies were
identified by hand searching references of included stu-
dies. We used various combinations of diarrhea, children,
cholera, shigella, rotavirus, ETEC and vaccines and
included studies in any language.
Inclusion criteria
Studies were included if they reported the effect of vac-
cines on morbidity and mortality associated with diarrhea
due to cholera, shigella, ETEC and rotavirus in children
under five years of age, as observed by morbidity and mor-
tality outcomes. We also included studies that were con-
ducted on a broader age group but had segregated data for
the defined age group. We also included studies reporting
on immunogenicity and adverse events outcomes. Only
studies with a placebo group or a control group were
included. Our original inclusion criteria included studies
with children aged up to 5 years, however for shigella vac-
cines, we found one study in the defined age group hence
we expanded our inclusion criteria to include children up
to sixteen years of age.
Abstraction, analysis and summary measure
We abstracted data for studies that met the final inclusion
and exclusion criteria. Data describing study identifiers and
context, study design and limitations, intervention specifics
and outcome effects, were abstracted into a standardized
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abstraction sheet as detailed in the CHERG Systematic
Review Guidelines. Each study was assessed and graded
according to the CHERG adaptation of the GRADE techni-
que. Randomized trials received an initial score of “high”.
We deducted a grade point for each study design
limitation.
Quantitative data synthesis
We conducted a meta-analysis for individual studies
and pooled statistics was reported as the relative risk
(RR) between the experimental and control groups
with 95% confidence intervals (CI). Mantel–Haenszel
pooled RR and corresponding 95% CI were reported or
the DerSimonian–Laird pooled RR and corresponding
95% CI where there was an unexplained heterogeneity.
All analyses were conducted using the software Review
Manager 5.1. Heterogeneity was quantified by Chi2 and I2,
which can be interpreted as the percentage of the total
variation between studies that is attributable to heteroge-
neity rather than to chance, a low p-value (less than 0.1)
or a large chi-squared statistic relative to its degree of free-
dom and I2 values greater than 50% were taken as substan-
tial and high heterogeneity. In situations of high
heterogeneity, causes were explored by sensitivity analysis
and random effect models were used.
We summarized the evidence by outcome, including
assessments of study quality and the quantitative mea-
sures, according to the standard guidelines. A grade of
“high”, “moderate”, “low” and “very low” was used for
grading the overall evidence indicating the strength of an
effect on specific health outcome according to the CHERG
Rules for Evidence Review.
Results
Cholera
We identified 1725 titles from search conducted in all
databases. After screening titles and abstracts, 12
[5,6,23-33] studies were identified that met the inclusion
criteria (Figure 1). Ten of the studies were Randomized
Controlled Trials (RCTs) while one was a quasi-experi-
mental design and one was a case control study. All of
these studies were conducted in developing countries
and had evaluated the effect of oral vaccines including
WC, BS-WC and live oral vaccines. Greater than two
folds rise in the vibriocidal antibody titres was reported
by seven studies and it showed a significant increase
(RR of 2.24, 95% CI: 1.32, 3.80). Sub group analysis
showed that killed oral vaccines were associated with a
non-significant rise in vibriocidal antibody titres (RR:
0.97, 95% CI: 0.75, 1.25), while live oral vaccines were
associated with a significant rise (RR: 10.73, 95% CI:
1.94, 59.33). For assessment of outcomes related to the
incidence of cholera, we reviewed both effectiveness and
efficacy trials. Three data sets from two studies showed
that cholera vaccination with a one year follow up were
associated with a 52% reduction (RR: 0.48, 95% CI: 0.35,
0.64) in the incidence of cholera based on the effective-
ness trials, while analysis of efficacy studies showed a
non-significant reduction of 10% (RR: 0.90, 95% CI:
0.40, 2.03). While sub group analysis based on vaccine
type, showed that; WC was associated with a 47% reduc-
tion (RR: 0.53, 95% CI: 0.36, 0.76), BS-WC was asso-
ciated with a 53% reduction (RR: 0.47, 95% CI: 0.30,
0.74) and live oral CVD 103-Hg R with a non-significant
impact (RR: 1.00, 95% CI: 0.20, 5.00) on the incidence of
cholera at one year follow up, although only a single
study was pooled for the latter two. Adverse events just
after the vaccination were also pooled and included
fever, nausea, vomiting, abdominal pain and diarrhea
with a RR of 1.42 (95% CI: 1.06, 1.89) (Table 1). Given
the design and standard of care in RCTs it was not pos-
sible to assess mortality impact.
Shigella
It is recognized that there are no commercially licensed
shigella vaccines, although several candidates have been
studied in humans. A total of eight [34-41] studies were
selected which met the inclusion criteria (Figure 2). All
were RCTs and three were from developing countries.
Vaccines for two shigella strains (shigella flexneri and
shigella sonnei) were evaluated by these studies. No
study reported on the outcome of mortality, while three
reported on morbidity; which was the incidence of shi-
gella. The analysis showed that shigella vaccine for
S. flexneri was associated with a non-significant 28%
reduction (RR: 0.72, 95% CI: 0.37, 1.39), while vaccines
for S.sonnei were associated with a non-significant 53%
reduction (RR: 0.47, 95% CI: 0.12, 1.85) in the incidence
of S. flexneri and S. sonnnei respectively. Subgroup ana-
lysis based on the type of vaccines (oral and parenteral)
also showed non-significant results for both the vaccines.
Two studies reported on adverse events after vaccination
and did not show any significant excess (RR 1.58, 95% CI:
0.81, 3.07) (Table 2).
ETEC
Similar to Shigella, there are no licensed ETEC vaccines.
We identified 1247 titles from our search of which only
six [42-47] studies were reviewed that matched our inclu-
sion criteria (Figure 3). Five of the identified studies were
RCTs. All of these were conducted in either Egypt or
Bangladesh. Studies provided data on immunogenicity
and adverse events but expectably, none had information
on morbidity or mortality . Two studies were pooled for
IgA seroconversion with a RR of 2.70 (95% CI: 1.87, 3.90)
and two for IgG seroconversion with a RR of 4.99 (95%
CI: 2.51, 9.92). Adverse events after the vaccination had a
RR of 1.58 (95% CI: 1.4, 2.19) (Table 3).
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Rotavirus
For rotavirus vaccine, we updated the previous review
and ran a search after the last search date and found five
new efficacy studies [48-52] which were included and no
new effectiveness studies were found. We identified new
studies reporting on outcomes of rotavirus hospitaliza-
tions (n=2); diarrhea hospitalizations (n=2); severe rota-
virus gastroenteritis (n=5); severe diarrhea (n=4); and
rotavirus gastroenteritis of any severity (n=3). All the
new data was entered with the previous estimates and
reanalyzed. There was no change in the effectiveness out-
comes as no new study was identified while the new esti-
mates for the efficacy outcomes are reported in table 4.
Results from two new large studies from Bangladesh and
India are expected within 2013 and should provide much
needed information on the effectiveness of rotavirus vac-
cines in South Asia. In the interval surveillance data from
several countries in Latin America, notably from Mexico
[54] does show a significant impact of childhood diarrhea
mortality since the introduction of the rotavirus vaccine.
Recommendation for the LiST model
The principal objective of our exercise was to provide
some estimates of vaccine effectiveness (for current and
potential future vaccines) on childhood diarrhea and
mortality for LiST. While we applied the CHERG rules
for evidence review to available outcomes, there were
several limitations in the available trial data. For cholera
vaccines, there was no mortality data so we used esti-
mates based on reduction in the frequency of severe cho-
lera-associated morbidity, which is the cholera incidence
to estimate a 52% reduction in the incidence of cholera
after vaccination against cholera. For rotavirus vaccines,
we did not find any further effectiveness trial hence the
recommendation stays the same that is a 74% reduction
in rotavirus specific mortality based on severe morbidity.
For ETEC vaccines we did not find any outcome which
could be projected to estimate the effect of ETEC vac-
cines on mortality although several trials of ETEC vac-
cines in travelers indicated that they have their greatest
impact against moderate to severe disease [18,19]. This
may be an important outcome to assess in future ETEC
efficacy and effectiveness studies once promising vaccine
currently under development move into this stage of field
testing. For shigella vaccines, currently there is no evi-
dence against mortality and the evidence on protective
efficacy against illness is also limited, like ETEC, in the
context of modeling for LiST.
Discussion
Diarrheal diseases continue to claim approximately 0.75
million lives of children below the age of 5 [1]. The avail-
ability and usage of vaccines against four of the most
common pathogens of diarrhea could help in significantly
reducing this burden, although the development process
for all vaccines is unequal. Our analysis shows that while
one could potentially reduce a substantial number of
rotavirus associated deaths and possibly for cholera in
appropriate contexts, the same cannot be said for shigella
and ETEC. The current data on the latter two vaccines is
hampered by lack of licensed vaccines for public health
use and adequate trials to assess efficacy in appropriate
settings particularly against more moderate to severe
form of illnesses.
We were able to generate potential estimates for efficacy/
effectiveness for the two licensed vaccines based on current
data. We estimated a summary impact estimate of 52%
reduction in the incidence of cholera with the use of cho-
lera vaccines. Although the quality of evidence was low
and only two studies were evaluated, both were from ende-
mic populations in developing countries and from effec-
tiveness trials. The vaccines evaluated included oral WC
and BS-WC which are currently available and licensed
and can be potentially used among susceptible populations.
Figure 1 Search strategy flow chart for Cholera
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Table 1 Quality assessment of vaccine trials for immunization against – cholera
Quality Assessment Summary of Findings
Directness No of events




Intervention Control Risk Ratio
Effectiveness against morbidity, Cholera Infection: Low-outcome-specific quality
02 [6,32] RCT/
Quasi
One study was a Quasi
Experimental Design
All studies show consistent
benefit
Results can be generalised to
population in developing
countries
Included WC and BS-WC
oral vaccines
63 75 0.48 [0.35, 0.64]a
O1 [5] Case
Control
Random model used Study was conducted in
Mozambique
BS-WC vaccine 2 22 0.18 (0.03, 1.08)
Efficacy against morbidity, Cholera Infection: High-outcome-specific quality
02 [29,33] RCT All studies show consistent
benefit
Results can be generalised to
population in developing
countries
Included WC and CVD
103-HgR live oral
Vaccines
11 13 0.90 [0.40, 2.03]a
Efficacy/Effectiveness against morbidity- Cholera Infection (Various Types of vaccines)
03 [6,32,33] RCT/
Quasi





Results can be generalised to
population in developing
countries
WC Vaccines 45 85 0.53 [0.36, 0.76]b
01 [32] RCT Only one study Study was conducted in
Bangladesh
BS-WC Vaccines 26 56 0.47 [0.30, 0.74]
01 [29] RCT Only one study Study was conducted in
Indonesia
CVD 103-HgR live oral 03 03 1.00 [0.20, 5.00]
Vibriocidal antibody: Low outcome-specific quality
07 [23,25,27-30,65] RCT None Results from analysis
significant. Five studies show
benefit
All from Developing Countries All Oral Vaccines 503 234 2.24 (1.32, 3.80)b
03 [23,27,31] RCT Two studies show benefit All from Developing Countries Oral Killed Vaccines 202 205 0.97 [0.75, 1.25]b
04 [25,28-30] RCT Three studies show significant
benefit
All from Developing Countries Oral Live Vaccines 301 29 10.73 [1.94, 59.37]b
One or more Adverse effect: Low outcome-specific quality
06
[24,25,27,28,30,32,33]
RCT None significant results All from developing countries All Oral Vaccines 132 91 1.42 (1.06, 1.89)a
a: Fixed Effect Model




















For rotavirus vaccine we estimated that currently marketed
rotavirus vaccines could prevent 74% (35–90%) of rotavirus
deaths and 47–57% of rotavirus hospitalizations but varia-
bility in efficacy in various geographic settings is recog-
nized. Rotavirus vaccines, thus, have the potential to
greatly reduce the fraction of diarrhea deaths due to rota-
virus. These estimates will be revised once the newer data
from trials in south Asia become available. We were unable
to estimate any effect sizes for mortality reduction with
potential shigella and ETEC vaccines as much of the data
from experimental vaccines is on immunogenicity with no
evidence of impact on disease burden.
Notwithstanding the need to integrate preventive strate-
gies against common diarrhea pathogens and disease bur-
den, vaccination strategies are important adjunctive
interventions and could impact mortality and morbidity
[53,54]. While the use of rotavirus vaccines has been
recommended by WHO [57], the potential role and usage
Figure 2 Search strategy flow chart for Shigella
Table 2 Quality assessment of vaccine trials for immunization against – Shigella
Quality Assessment Summary of Findings
Directness No of events
No of
Studies





Intervention Control Risk Ratio












Two used oral vaccine
while one used
intramuscular











Oral Vaccines 49 99 0.67 [0.28, 1.59]b
01 [40] RCT Only one study Study was
conducted in Israel
Parenteral Vaccine 07 08 0.92 [0.33, 2.53]












Two used oral vaccine
while one used
intramuscular











Oral Vaccines 10 56 0.39 [0.04, 4.33]b
01 [40] RCT Only one study Study was
conducted in Israel
Parenteral Vaccines 29 38 0.73 [0.45, 1.17]








45 08 1.58(0.81, 3.07)a
a: Fixed Effect Model
b: Random Effect Model
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of oral cholera vaccines as an adjunct to the control of
cholera in endemic areas and during outbreaks is unclear.
The reformulation of a bivalent WC oral vaccine is an
affordable and safe for use in cholera endemic areas and
can be an exciting development. Our meta-analysis of chil-
dren under 5 years of age shows a significant 52% reduc-
tion in the number of cholera cases by the use of the
vaccine in endemic populations.
The case for other vaccines is less clear because of lim-
ited information. Only a limited number of ETEC vaccine
trials that have been conducted among younger age
groups in endemic areas with only one Phase 3 efficacy
trial which was also not able to determine the vaccines
impact against more severe or life threatening ETEC dis-
ease [18,19]. ETEC vaccine has shown to be a feasible
strategy based on the observation that immunity may be
acquired through natural infections, [55,56] which is
further supported by the observed decrease in ETEC-
related events after the first year of life where ETEC infec-
tions are prevalent [57,58]. There are various challenges
concerning the development of an effective and safe vac-
cine for children in developing countries, the most signifi-
cant being the reduced immunogenicity and protective
efficacy of oral vaccines in this population [59-62]. Despite
such limitations, the analysis of the ETEC-rCTB vaccine
suggests that it is immunogenic and relatively safe.
Unpublished data from an efficacy trial among Egyptian
children showed limited benefit, although the WHO
recommended further testing after reformulation of the
vaccine to contain more CFA antigens and modification of
the surveillance approach to capture impact on more
severe forms of ETEC infections [63]. A re-formulated ver-
sion of this vaccine containing more CFA’s per dose has
recently gone back into clinical trials with the new muco-
sal adjuvant, dmLT [18].
Like for ETEC, there are currently no licensed Shigella
vaccines despite their development being a WHO priority
for over 20 years. An expert panel convened by the Child
Health and Nutrition Research Initiative (CHNRI) of the
World Bank identified Shigella one of the highest priorities
for long-term vaccine development [64]. In practice,
the greatest impact on mortality of enteric vaccines, like
Shigella, will be seen in medically underserved populations
[65] and a safe, effective, and practical Shigella vaccine
would likely save tens of thousands of lives and prevent
hundreds of thousands of diarrheal illnesses in the devel-
oping world and in international travelers. Limited field
trials of early live attenuated vaccine candidates or more
recently, trials of polysaccharide based conjugate vaccines
have shown vaccination to be a potentially effective public
health tool in disease prevention and control [39,40] but
currently there are no commercial products in the market.
However, there are several promising candidates in the
development pipeline, including the evaluation of con-
served Shigella invasion proteins that may help broaden
vaccine coverage [66].
Figure 3 Search strategy flow chart for ETEC
Table 3 Quality assessment of vaccine trials for immunization against – ETEC
Results for ETEC
Outcomes No of Studies No of Participants Impact Estimates (95% CI)
Serum Ig A seroconversion 2 [42,47] 157 2.70 [1.87, 3.90]a
Serum Ig G seroconversion 2 [42,47] 157 4.99 [2.51, 9.92]a
Adverse Events 4 [43,44,46,47] 1169 1.58 (1.14, 2.19)a
a: Fixed Effect Model
b: Random Effect Model
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Table 4 Quality assessment of vaccine trials for immunization against – Rotavirus
Quality Assessment Summary of Findings
Directness No of events
No of
Studies
Design Limitations Consistency Generalizability to population of
interest
Generalizability to intervention of
interest
Intervention Control Relative Risk (95%
CI)







NA Urban and peri-urban hospitals in
Nicaragua
Pentavalent vaccine 43 255 74% (35–90%)







NA Urban and peri-urban hospitals in
Nicaragua
Pentavalent vaccine 155 926 61% (38–75%)




None NA Urban and peri-urban hospitals in
Nicaragua (-0.5)




None NA Rural hospital in the Northern
Territory of Australia
Monovalent vaccine 10 58 57% (<0–83%)
Efficacy against severe rotavirus infection: High outcome-specific quality
Eight RCT None Heterogeneity from meta-
analysis all studies show benefit
Four studies from developing and
four from developed countries
Two used Monovalent Vaccine 237 745 0.17 [0.09, 0.32]b
Efficacy against severe GI infection: Moderate outcome-specific quality
Six RCT None All studies show benefit Two from developed countries Two used Monovalent Vaccine 1328 1573 0.68 [0.57, 0.81]b
Efficacy against rotavirus hospitalizations: Moderate outcome-specific quality
Five RCT None All studies show benefit Four studies from developed
countries
Two used Monovalent Vaccine 46 329 0.11 [0.05, 0.27]b
Efficacy against GI hospitalizations: Moderate outcome-specific quality
Two RCT None All studies show benefit USA, Europe and Latin America Two of three studies used
monovalent vaccine; one used
pentavalent.
203 607 0.43 (0.21, 0.9)b
Efficacy against any rotavirus: High outcome-specific quality
Five RCT None All studies show benefit Four studies from developed
countries
One study used monovalent vaccine 586 1348 0.39 [0.25, 0.61]b
a: Fixed Effect Model




















The use of vaccines seems a more applicable near-term
solution due to its potential cost-effectiveness, and thus
constitutes a promising alternative strategy. While the
results have so far been quite favorable, current research
on vaccines is still quite limited, though it is said to
represent more activity in the field than we have pre-
viously seen [67]. For example, there is currently only
one vaccine that is at the forefront of pediatric ETEC
research: the ETEC/rCTB vaccine, similarly more empha-
sis has been laid on the killed oral cholera vaccine than
on any other form of the vaccine, with a majority of stu-
dies coming in from Bangladesh and Vietnam, hampering
the generalizability of results, with similar limitations
observed in studies with shigella and rotavirus as well. It
is therefore important to underscore the importance of
continued research in varying contexts to help refine and
define global policies for the use of vaccines for the con-
trol of diarrheal disorders.
Abbreviations
CHERG: Child Health Epidemiology Reference Group; CI: Confidence Intervals;
ETEC: Enterotoxigenic Escherichia coli (ETEC); GRADE: Grading of
Recommendations, Assessments, Development and Education; LiST: Lives
Saved Tools; OCV: Oral Cholera Vaccines; rBS-WC: killed whole cell plus
recombinant cholera toxin B subunit vaccine; RCTs: Randomized Controlled
Trials; RR: Relative Risk; WC: killed oral cholera vaccine; WHO: World Health
Organization.
Conflict of interests
The authors declare that they have no conflict of interest.
Authors’ contributions
Dr ZAB was responsible for designing the review and co-ordinating the
review with JKD. AT, AH, AL and CD were responsible for: data collection,
screening the search results, screening retrieved papers against inclusion
criteria, appraising quality of papers, abstracting data from papers, entering
data into RevMan and analysis for shigella vaccines, cholera vaccines,
rotavirus vaccines and ETEC vaccines respectively. ZAB and JKD supervised
the project, interpreted the data and wrote the review. ZAB critically
reviewed and modified the manuscript.
Acknowledgment
This work was supported in part by a grant from the Bill & Melinda Gates
Foundation (OPP1004060) to Evidence-based landscape analysis on
Childhood Diarrheal disorders and development of global consensus on
priorities for research and interventions. We acknowledge the support and
guidance of Myron Levine especially for the shigella vaccine review and
David Sack for his inputs on the cholera vaccine review. We would also
thank the reviewers of this manuscript for all their valuable inputs and
suggestions.
Declaration
The publication costs for this supplement were funded by a grant from the
Bill & Melinda Gates Foundation to the US Fund for UNICEF (grant 43386 to
“Promote evidence-based decision making in designing maternal, neonatal,
and child health interventions in low- and middle-income countries”). The
Supplement Editor is the principal investigator and lead in the development
of the Lives Saved Tool (LiST), supported by grant 43386. He declares that
he has no competing interests.
This article has been published as part of BMC Public Health Volume 13
Supplement 3, 2013: The Lives Saved Tool in 2013: new capabilities and
applications. The full contents of the supplement are available online at
http://www.biomedcentral.com/bmcpublichealth/supplements/13/S3.
Authors’ details
1Division of Women & Child Health, The Aga Khan University, Karachi,
Pakistan. 2Global Child Health and Policy, Centre for Global Child Health, The
Hospital for Sick Children, Toronto, ON, Canada.
Published: 17 September 2013
References
1. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I,
Campbell H, Cibulskis R, Li M, Mathers C, Black RE, Child Health
Epidemiology Reference Group of WHO and UNICEF: Global, regional, and
national causes of child mortality: an updated systematic analysis for
2010 with time trends since 2000. Lancet 2012, 379:2151-2161.
2. World Health Organization: Diarrhoeal Diseases (Updated February 2009).
Initiative for Vaccine Research (IVR);, Accessed from http://www.who.int/
vaccine_research/diseases/diarrhoeal/en/index6.html.
3. Peirano G, Souza FS, Rodrigues DP: Frequency of serovars and
antimicrobial resistance in Shigella spp. from Brazil. Memorias do Instituto
Oswaldo Cruz 2006, 101(3):245-250.
4. Wenneras C, Erling V: Prevalence of enterotoxigenic Escherichia coli-
associated diarrhoea and carrier state in the developing world. J Health
Popul Nutr 2004, 22(4):370-382.
5. Lucas MES, Deen JL, Von Seidlein L, Wang XY, Ampuero J, Puri M, Ali M,
Ansaruzzaman M, Amos J, Macuamule A: Effectiveness of mass oral
cholera vaccination in Beira, Mozambique. New England Journal of
Medicine 2005, 352(8):757-767.
6. Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, Hang PVD,
Rao MR: Field trial of a locally produced, killed, oral cholera vaccine in
Vietnam. Lancet 1997, 349(9047):231-235.
7. Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J,
Clemens JD: Herd immunity conferred by killed oral cholera vaccines in
Bangladesh: a reanalysis. Lancet 2005, 366(9479):44-49.
8. Longini IM Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD:
Controlling endemic cholera with oral vaccines. PLoS medicine 2007,
4(11):e336.
9. Mel DM, Arsic BL, Nikolic BD, Radovanic ML: Studies on vaccination
against bacillary dysentery. Bull WHO 1968, 39:375-380.
10. Terzin AL, Vuksic CL: Studies on Vaccination against Bacillary Dysentery.
Bull Wld Hlth Org 1965, 32:637-645.
11. Van De Verg LL, Bendiuk NO, Kotloff K, Marsh MM, Ruckert JL, Puryear JL,
Taylor DN, Hartman AB: Cross-reactivity of Shigella flexneri serotype 2a O
antigen antibodies following immunization or infection. Vaccine 1996,
14(11):1062-1068.
12. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ,
Adak GK, Levine MM: Global burden of Shigella infections: implications
for vaccine development and implementation of control strategies.
Bulletin of the World Health Organization 1999, 77(8):651-666.
13. Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM: Strategy
for cross-protection among Shigella flexneri serotypes. Infection and
immunity 1999, 67(2):782-788.
14. Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM,
Mellado-Sanchez G, Clements JD, Pasetti MF, Picking WL: Broadly
Protective Shigella Vaccine Based on Type III Secretion Apparatus
Proteins. Infection and immunity 2012, 80(3):1222-1231.
15. Gupta SK, Keck J, Ram PK, Crump JA, Miller MA, Mintz ED: Part III. Analysis
of data gaps pertaining to enterotoxigenic Escherichia coli infections in
low and medium human development index countries, 1984-2005.
Epidemiology and infection 2008, 136(6):721-738.
16. Qadri F, Saha A, Ahmed T, Al Tarique A, Begum YA, Svennerholm AM:
Disease burden due to enterotoxigenic Escherichia coli in the first 2
years of life in an urban community in Bangladesh. Infect Immun 2007,
75(8):3961-3968.
17. Rao MR, Abu-Elyazeed R, Savarino SJ, Naficy AB, Wierzba TF, Abdel-Messih I,
Shaheen H, Frenck RW Jr., Svennerholm AM, Clemens JD: High disease
burden of diarrhea due to enterotoxigenic Escherichia coli among rural
Egyptian infants and young children. J Clin Microbiol 2003,
41(10):4862-4864.
18. Zhang W, Sack DA: Progress and hurdles in the development of vaccines
against enterotoxigenic Escherichia coli in humans. Expert Review of
Vaccines 2012, 11(6):677-694.
Das et al. BMC Public Health 2013, 13(Suppl 3):S11
http://www.biomedcentral.com/1471-2458/13/S3/S11
Page 9 of 11
19. Svennerholm AM, Tobias J: Vaccines against enterotoxigenic Escherichia
coli. Expert Rev Vaccines 2008, 7(6):795-804.
20. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B,
Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM: Effect of human
rotavirus vaccine on severe diarrhea in African infants. N Engl J Med
2010, 362(4):289-298.
21. Munos MK, Walker CLF, Black RE: The effect of rotavirus vaccine on
diarrhoea mortality. International journal of epidemiology 2010, 39(suppl 1):
i56-i62.
22. Walker N, Fischer-Walker C, Bryce J, Bahl R, Cousens S: Standards for
CHERG reviews of intervention effects on child survival. International
journal of epidemiology 2010, 39(suppl 1):i21-i31.
23. Ahmed T, Svennerholm AM, Tarique AA, Sultana GNN, Qadri F: Enhanced
immunogenicity of an oral inactivated cholera vaccine in infants in
Bangladesh obtained by zinc supplementation and by temporary
withholding breast-feeding. Vaccine 2009, 27(9):1433-1439.
24. Concha A, Giraldo A, Castaneda E, Martinez M, Hoz Fdl, Rivas F, et al: Safety
and immunogenicity of oral killed whole cell recombinant B subunit
cholera vaccine in Barranquilla, Colombia. Bulletin of the Pan American
Health Organization 1995, 29(4):312-321.
25. Lagos R, San Martin O, Wasserman SS, Prado V, Losonsky GA, Bustamante C,
Levine MM: Palatability, reactogenicity and immunogenicity of
engineered live oral cholera vaccine CVD 103-HgR in Chilean infants
and toddlers. Pediatr Infect Dis J 1999, 18(7):624-630.
26. Lucas MES, Jeuland M, Deen J, Lazaro N, MacMahon M, Nyamete A,
Barreto A, von Seidlein L, Cumbane A, Songane FF: Private demand for
cholera vaccines in Beira, Mozambique. Vaccine 2007, 25(14):2599-2609.
27. Matsuda F, Chowdhury MI, Saha A, Asahara T, Nomoto K, Tarique AA,
Ahmed T, Nishibuchi M, Cravioto A, Qadri F: Evaluation of a probiotics,
Bifidobacterium breve BBG-01, for enhancement of immunogenicity of
an oral inactivated cholera vaccine and safety: A randomized, double-
blind, placebo-controlled trial in Bangladeshi children under 5 years of
age. Vaccine 2011, 29(10):1855-1858.
28. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA,
Saha A, Al Tarique A, Seidlein LV, Park E: Peru-15, a live attenuated oral
cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and
infants. Vaccine 2007, 25(2):231-238.
29. Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM,
Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM,
et al: Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR
in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000,
18(22):2399-2410.
30. Simanjuntak CH, O’Hanley P, Punjabi NH, Noriega F, Pazzaglia G, Dykstra P,
Kay B, Suharyono , Budiarso A, Rifai AR, et al: Safety, immunogenicity, and
transmissibility of single-dose live oral cholera vaccine strain CVD 103-
HgR in 24- to 59-month-old Indonesian children. J Infect Dis 1993,
168(5):1169-1176.
31. Taylor DN, Cardenas V, Perez J, Puga R, Svennerholm AM: Safety,
immunogenicity, and lot stability of the whole cell/recombinant B
subunit (WC/rCTB) cholera vaccine in Peruvian adults and children. The
American journal of tropical medicine and hygiene 1999, 61(6):869.
32. Van Loon FPL, Clemens JD, Chakraborty J, Rao MR, Kay BA, Sack DA,
Yunus M, Ali M, Svennerholm AM, Holmgren J: Field trial of inactivated
oral cholera vaccines in Bangladesh: results from 5 years of follow-up.
Vaccine 1996, 14(2):162-166.
33. Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK,
Sarkar B, Puri MK, et al: Efficacy of a low-cost, inactivated whole-cell oral
cholera vaccine: results from 3 years of follow-up of a randomized,
controlled trial. PLoS Negl Trop Dis 2011, 5(10):e1289.
34. Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R,
Majadly F, Bryla DA, Karpas AB, et al: Safety and immunogenicity of
Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide
conjugates in children. J Infect Dis 1999, 179(6):1565-1568.
35. Levine MM, Gangarosa EJ, Werner M, Morris GK: Shigellosis in custodial
institutions. 3. Prospective clinical and bacteriologic surveillance of
children vaccinated with oral attenuated shigella vaccines. J Pediatr 1974,
84(6):803-806.
36. Li A, Cam PD, Islam D, Minh NB, Huan PT, Rong ZC, Karlsson K, Lindberg G,
Lindberg AA: Immune responses in Vietnamese children after a single
dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124.
J Infect 1994, 28(1):11-23.
37. Linde K, Randhagen B, Beer J, Dentchev V, Marinova S, Vassilev T,
Bratoyeva M: Shigella flexneri 2a and sonnei I vaccine with two
attenuating markers: construction, tolerability and immunogenicity in
143 children aged 3-17 years. Vaccine 1993, 11(2):197-199.
38. Mel D, Gangarosa EJ, Radovanovic ML, Arsic BL, Litvinjenko S: Studies on
vaccination against bacillary dysentery. 6. Protection of children by oral
immunization with streptomycin-dependent Shigella strains. Bull World
Health Organ 1971, 45(4):457-464.
39. Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L,
Levi Y, Chu C, Shiloach J, et al: Safety and immunogenicity of Shigella
sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in
one- to four-year-old children. Pediatr Infect Dis J 2003, 22(8):701-706.
40. Passwell JH, Ashkenzi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-
Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, et al: Age-related
efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old
Israeli children. Vaccine 2010, 28(10):2231-2235.
41. Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M, Begum N,
Islam MS, Sohel BM, Venkatesan M, et al: Safety, dose, immunogenicity,
and transmissibility of an oral live attenuated Shigella flexneri 2a
vaccine candidate (SC602) among healthy adults and school children in
Matlab, Bangladesh. Vaccine 2011, 29(6):1347-1354.
42. Hall ER, Wierzba TF, Ahren C, Rao MR, Bassily S, Francis W, Girgis FY,
Safwat M, Lee YJ, Svennerholm AM, et al: Induction of systemic
antifimbria and antitoxin antibody responses in Egyptian children and
adults by an oral, killed enterotoxigenic Escherichia coli plus cholera
toxin B subunit vaccine. Infect Immun 2001, 69(5):2853-2857.
43. Qadri F, Ahmed F, Ahmed T, Svennerholm AM: Homologous and cross-
reactive immune responses to enterotoxigenic Escherichia coli
colonization factors in Bangladeshi children. Infect Immun 2006,
74(8):4512-4518.
44. Qadri F, Ahmed T, Ahmed F, Bradley Sack R, Sack DA, Svennerholm AM:
Safety and immunogenicity of an oral, inactivated enterotoxigenic
Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi
children 18-36 months of age. Vaccine 2003, 21(19-20):2394-2403.
45. Qadri F, Wenneras C, Ahmed F, Asaduzzaman M, Saha D, Albert MJ,
Sack RB, Svennerholm A: Safety and immunogenicity of an oral,
inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit
vaccine in Bangladeshi adults and children. Vaccine 2000,
18(24):2704-2712.
46. Savarino SJ, Hall ER, Bassily S, Brown FM, Youssef F, Wierzba TF, Peruski L,
El-Masry NA, Safwat M, Rao M, et al: Oral, inactivated, whole cell
enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine:
results of the initial evaluation in children. PRIDE Study Group. J Infect
Dis 1999, 179(1):107-114.
47. Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF Jr., Abu-
Elyazeed R, Rao M, Francis WM, El Mohamady H, et al: Introductory
evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli
plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis
J 2002, 21(4):322-330.
48. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN,
Steele AD, Laserson KF, Ansah NA, et al: Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in developing
countries in sub-Saharan Africa: a randomised, double-blind, placebo-
controlled trial. Lancet 2010, 376(9741):606-614.
49. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B,
Victor JC, Gillard PH, Cheuvart BB, et al: Effect of human rotavirus vaccine
on severe diarrhea in African infants. N Engl J Med 2010, 362(4):289-298.
50. Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, Lee BW, Teoh YL,
Tang H, Boudville I, et al: Safety and efficacy of human rotavirus vaccine
during the first 2 years of life in Asian infants: randomised, double-blind,
controlled study. Vaccine 2009, 27(43):5936-5941.
51. Vesikari T, Karvonen A, Ferrante SA, Ciarlet M: Efficacy of the pentavalent
rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the
Finnish Extension Study. Eur J Pediatr 2010, 169(11):1379-1386.
52. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT,
Le TP, Luby SP, et al: Efficacy of pentavalent rotavirus vaccine against
severe rotavirus gastroenteritis in infants in developing countries in
Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010,
376(9741):615-623.
53. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P,
Campbell H, Walker CF, Cibulskis R, et al: Global, regional, and national
Das et al. BMC Public Health 2013, 13(Suppl 3):S11
http://www.biomedcentral.com/1471-2458/13/S3/S11
Page 10 of 11
causes of child mortality in 2008: a systematic analysis. Lancet 2010,
375(9730):1969- 1987.
54. Guerrant RL, Kosek M, Moore S, Lorntz B, Brantley R, Lima AAM: Magnitude
and impact of diarrheal diseases. Archives of medical research 2002,
33(4):351-355.
55. Levine M, Nalin D, Hoover D, Bergquist E, Hornick R, Young C: Immunity to
enterotoxigenic Escherichia coli. Infect Immun 1979, 23:729-736.
56. Steinsland H, Valentiner-Branth P, Gjessing H, Aaby P, Molbak K,
Sommerfelt H: Protection from natural infections with enterotoxigenic
Escherichia coli: longitudinal study. Lancet 2003, 362(9380):286-291.
57. Rao M, Abu-Elyazeed R, Savarino S, Naficy A, Wierzba T, Abdel-Messih I,
et al: High disease burden of diarrhea due to enterotoxigenic Escherichia
coli among rural Egyptian infants and young children. J Clin Microbiol
2003, 41:4862-4864.
58. Walker RI, Steele D, Aguado T, Ad Hoc ETEC: Analysis of strategies to
successfully vaccinate infants in developing countries against
enterotoxigenic E. coli (ETEC) disease. Vaccine 2007, 25(14):2545-2566.
59. Svennerholm A-M: From cholera to enterotoxigenic Escherichia coli
(ETEC) vaccine development. The Indian journal of medical research 2011,
133(2):188-194.
60. Czerkinsky C, Holmgren J: Enteric vaccines for the developing world: a
challenge for mucosal immunology. Mucosal Immunology 2009,
2(4):284-287.
61. Sack DA, Qadri F, Svennerholm A: Determinants of responses to oral
vaccines in developing countries. Annales Nestle, English Ed 2008,
66(2):71-79.
62. Imdad A, Herzer K, Mayo-Wilson E, Yakoob MY, Bhutta ZA: Vitamin A
supplementation for preventing morbidity and mortality in children
from 6 months to 5 years of age. Cochrane Database Syst Rev 2010, , 12:
CD008524.
63. Rowe AK, de Savigny D, Lanata CF, Victora CG: How can we achieve and
maintain high-quality performance of health workers in low-resource
settings? Lancet 2005, 366(9490):1026-1035.
64. Kosek M, Lanata CF, Black RE, Walker DG, Snyder JD, Salam MA,
Mahalanabis D, Fontaine O, Bhutta ZA, Bhatnagar S, et al: Directing
diarrhoeal disease research towards disease-burden reduction. J Health
Popul Nutr 2009, 27(3):319-331.
65. Clemens J: Evaluation of vaccines against enteric infections: a clinical
and public health research agenda for developing countries. Philos Trans
R Soc Lond B Biol Sci 2011, 366:2799-2805.
66. Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM,
Mellado-Sanchez G, Clements JD, Pasetti MF, Picking WL: Broadly
protective Shigella vaccine based on type III secretion apparatus
proteins. Infect Immun 2012, 80(3):1222-1231.
67. Patriarca PA, Wright PF, John TJ: Factors affecting the immunogenicity of
oral poliovirus vaccine in developing countries: review. Rev Infect Dis
1991, 13(5):926-939.
doi:10.1186/1471-2458-13-S3-S11
Cite this article as: Das et al.: Vaccines for the prevention of diarrhea
due to cholera, shigella, ETEC and rotavirus. BMC Public Health 2013
13(Suppl 3):S11.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Das et al. BMC Public Health 2013, 13(Suppl 3):S11
http://www.biomedcentral.com/1471-2458/13/S3/S11
Page 11 of 11
